Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 3951 - 3975 of 6615 in total
Piclozotan has been investigated for the treatment of Parkinson's Disease.
Investigational
Matched Iupac: … 3-chloro-4-(4-{1',2',3',6'-tetrahydro-[2,4'-bipyridine]-1'-yl}butyl)-4,5-dihydro-1,4-benzoxazepin-5-one …
Matched Categories: … Serotonin 5-HT1 Receptor Agonists …
Investigational
Matched Iupac: … (3R)-1-azabicyclo[2.2.2]octan-3-yl 6-[(3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin …
Matched Categories: … Serotonin 5-HT4 Receptor Agonists …
β-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs). It may be a chemopreventive agent.
Experimental
Matched Description: … is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5' …
NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Investigational
Matched Description: … dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5- …
YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.
Investigational
Matched Description: … YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity …
Matched Categories: … Serotonin 5-HT2 Receptor Antagonists …
2,5-Dimethoxy-4-ethylthioamphetamine (ALEPH-2) is a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties.
Experimental
Matched Categories: … Serotonin 5-HT2 Receptor Agonists …
Velusetrag has been used in trials studying the treatment of Gastroparesis and Alzheimer's Disease. It is a highly selective serotonin receptor agonist effective in patients with chronic constipation. It is being developed by Theravance. Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research...
Investigational
Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease. Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties.
Investigational
Matched Description: … Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist …
Experimental
Matched Iupac: … {[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({[hydroxy({[(2R,3S,4S)-2,3,4 ... -trihydroxy-5-{6-hydroxy-7,8-dimethyl-2,4-dioxo-2H,3H,4H,10H-benzo[g]pteridin-10-yl}pentyl]oxy})phosphoryl …
Pyridoxamine has been used in trials studying the treatment of Kidney Stones.
Investigational
Matched Iupac: … 4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol …
A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of action may be similar to those of LSD.
Experimental
Illicit
Experimental
Matched Mixtures name: … CitraNatal 90 DHA …
AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation. It is being developed by Amira.
Investigational
Matched Description: … AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential …
Experimental
Matched Iupac: … (2R,3S)-2-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]-3-methylpentanoic …
Experimental
Matched Iupac: … (2S)-2-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]hexanoic acid …
Experimental
Matched Iupac: … (2S)-2-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]pentanoic acid …
Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology. This includes inverse agonist activity of H1 and 5-HT2 receptors and antagonism of α2-adrenergic receptors. Merck has...
Investigational
Matched Iupac: … (7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.0²,⁷.0⁸,¹³]nonadeca-1(15),8,10,12,16,18-hexaene …
Matched Description: … This includes inverse agonist activity of H1 and 5-HT2 receptors and antagonism of α2-adrenergic receptors …
Matched Salts cas: … 680993-85-5
Matched Categories: … Serotonin 5-HT2 Receptor Antagonists ... Serotonin 5-HT3 Receptor Antagonists …
Investigational
A synthetic steroid with progestational activity. It is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast Asia, though notably not in the United States or Canada.
Experimental
m-Chlorophenylpiperazine has been used in trials studying the treatment of Alcoholism.
Investigational
Matched Categories: … Serotonin 5-HT2 Receptor Agonists …
Displaying drugs 3951 - 3975 of 6615 in total